Second-generation CT scanner substantially reduces radiation exposure

January 31, 2013, Radiological Society of North America

Researchers using a newly approved advanced computed tomography (CT) system were able to significantly reduce radiation exposure in patients undergoing coronary CT angiography (CCTA), according to a new study published online in the journal Radiology.

" during diagnostic imaging is a substantial public concern," said Marcus Y. Chen, M.D., lead author of the study from the advanced cardiovascular imaging laboratory at the National Institutes of Health in Bethesda, Md. "Minimizing radiation exposure while maintaining diagnostic-quality scans is clearly feasible with this new second-generation 320–detector row CT scanner."

CCTA is a valuable noninvasive imaging exam with high . The exam is particularly effective and safe for the exclusion of significant in patients arriving at the emergency department with . However, the clinical benefit of CCTA has been tempered by concerns of potential future cancer risk from the radiation exposure. Technologic advances have evolved to allow radiologists to not only reduce radiation exposure to the patient but also to improve image ac¬quisition.

This study represents the initial coronary angiography results obtained with a prototype 320–detector row CT system recently approved by the U.S. . The new system holds several technical advantages over its first-generation counterpart, including a gantry rotation time of 275 milliseconds, wide volume coverage, iterative reconstruction, automated exposure control, and a larger x-ray power generator.

For the study, Dr. Chen and colleagues performed contrast–enhanced CCTA with a second-generation 320-slice CT system on 107 adult patients (mean age, 55.4) and compared radiation exposure and image quality to those of CCTA exams previously performed on 100 patients using a first-generation 320-slice scanner.

Effective radiation dose was estimated by multiplying the dose-length product—a calculation of the radiation dose for a series of scans or entire examination—by an effective dose conversion factor and reported with size-specific dose estimates (SSDEs). Image quality was evaluated by two independent readers.

The median radiation dose was 0.93 millisieverts (mSv) with the second-generation unit and 2.67 mSv with the first-generation unit. The median SSDE was 6.0 milligray (mGy) with the second-generation unit and 13.2 mGy with the first-generation unit. Overall, the radiation dose was less than 0.5 mSv for 23 of the 107 CT angiography examinations (21.5 percent), less than 1 mSv for 58 (54.2 percent), and less than 4 mSv for 103 (96.3 percent). All studies were of diagnostic quality, with most having excellent image quality.

"The second-generation provided excellent image quality over a wide range of body sizes and heart rates at low radiation doses," Dr. Chen said. "The low dose achieved during CT angiography could be used to minimize overall to the patient or to enable addi¬tional types of imaging within reasonable radiation doses."

Explore further: Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose

Related Stories

Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose

May 1, 2012
The use of a dedicated pediatric imaging department (with dedicated pediatric computed tomography (CT) technologists) for pediatric CT scans significantly reduces the radiation dose delivered to the patient, according to ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.